All In MedTech

Device Trial Radar · NCT03503877

Media, Morphokinetics, and Mosaicism

Aneuploidy Rates and Morphokinetic Parameters in Sibling Embryos Cultured in Distinct Culture Media

Last checked: Nov 19, 2026Latest source record: Dec 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

200

Actual

Start

Feb 14, 2018

Primary completion

Nov 28, 2019

Study completion Nov 28, 2019

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 20, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 42 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Embryonic aneuploidy is the underlying etiology for the majority of failed implantation and miscarriage. Preimplantation genetic screening (PGS) with transfer of a euploid embryo has been advocated as a strategy for increasing live birth rates with a single embryo transfer. Culturing embryos to the blastocyst stage for trophectoderm biopsy is a requirement for PGS. Several commercially-available single-step embryonic culture media with varying composition have been established for use in the IVF laboratory. Early reports have suggested differences in clinical outcomes, such as aneuploidy and miscarriage rates, with distinct culture media currently in standard use. However, there have been no clinical trials demonstrating the superiority of any one commercially-available culture media formulation. As a result, clinics use media with varying composition based upon familiarity and cost.

Conditions

  • Embryonic Mosaicism
  • Embryo Culture Media
  • Embryo Morphokinetics
  • Infertility

Interventions

  • EmbryoScope PlusDevice

    All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data

  • GLOBAL MEDIAOther

    Embryos will be cultured in GLOBAL media

  • SAGE MEDIAOther

    Embryos will be cultured in SAGE media

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Aneuploidy RatesTime frame: Preimplantation Genetic Testing at blastocyst stage of embryo development, 2 weeks from start of IVF treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.